{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:19:22Z","timestamp":1792815562032,"version":"4.5.0"},"reference-count":67,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamapsychiatry.2018.3126","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T11:32:23Z","timestamp":1544009543000},"page":"208","source":"Crossref","is-referenced-by-count":563,"title":["Prevention and Treatment of Opioid Misuse and Addiction"],"prefix":"10.1001","volume":"76","author":[{"given":"Nora D.","family":"Volkow","sequence":"first","affiliation":[{"name":"National Institute on Drug Abuse, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Jones","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Einstein","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Wargo","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"yrv180004r2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","article-title":"Overdose deaths involving opioids, cocaine, and psychostimulants\u2014United States, 2015\u20132016.","volume":"67","author":"Seth","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"yrv180004r4","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1038\/sj.npp.1301675","article-title":"The role of amygdalar mu-opioid receptors in anxiety-related responses in two rat models.","volume":"33","author":"Wilson","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"yrv180004r5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.neuropharm.2017.12.032","article-title":"Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression.","volume":"131","author":"Imam","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"yrv180004r6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1151\/spp","article-title":"The neurobiology of opioid dependence: implications for treatment.","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"issue":"3","key":"yrv180004r7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1037\/1064-1297.2.3.244","article-title":"Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey.","volume":"2","author":"Anthony","year":"1994","journal-title":"Exp Clin Psychopharmacol"},{"key":"yrv180004r8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/SAR","article-title":"Opioid-use disorder among patients on long-term opioid therapy: impact of final DSM-5 diagnostic criteria on prevalence and correlates.","volume":"6","author":"Boscarino","year":"2015","journal-title":"Subst Abuse Rehabil"},{"issue":"1","key":"yrv180004r9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction.","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"yrv180004r10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S2215-0366(16)00104-8","article-title":"Neurobiology of addiction: a neurocircuitry analysis.","volume":"3","author":"Koob","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"yrv180004r11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.7326\/M14-2775","article-title":"National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain.","volume":"162","author":"Reuben","year":"2015","journal-title":"Ann Intern Med"},{"key":"yrv180004r12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2016.06.029","article-title":"Opioid-induced hyperalgesia: cellular and molecular mechanisms.","volume":"338","author":"Roeckel","year":"2016","journal-title":"Neuroscience"},{"issue":"1","key":"yrv180004r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for Prescribing Opioids for Chronic Pain\u2013United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"7","key":"yrv180004r14","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years.","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"yrv180004r15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addbeh.2017.05.030","article-title":"Increased use of heroin as an initiating opioid of abuse.","volume":"74","author":"Cicero","year":"2017","journal-title":"Addict Behav"},{"issue":"31","key":"yrv180004r17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.15585\/mmwr.mm6531a2","article-title":"Incidence of neonatal abstinence syndrome\u201428 states, 1999\u20132013.","volume":"65","author":"Ko","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"yrv180004r18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/AOG.0000000000000208","article-title":"Increase in prescription opioid use during pregnancy among Medicaid-enrolled women.","volume":"123","author":"Desai","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"2","key":"yrv180004r19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejogrb.2005.08.010","article-title":"Pregnancy outcome in women who use opiates.","volume":"126","author":"Fajemirokun-Odudeyi","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"yrv180004r20","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1111\/pme.12914","article-title":"Opioid induced hyperalgesia.","volume":"16","author":"Yi","year":"2015","journal-title":"Pain Med"},{"issue":"9","key":"yrv180004r21","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/npp.2014.77","article-title":"Persistent pain facilitates response to morphine reward by downregulation of central amygdala GABAergic function.","volume":"39","author":"Zhang","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"yrv180004r22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3122\/jabfm.2017.04.170112","article-title":"Prescription opioid use among adults with mental health disorders in the United States.","volume":"30","author":"Davis","year":"2017","journal-title":"J Am Board Fam Med"},{"issue":"1-3","key":"yrv180004r23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2007.09.018","article-title":"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates.","volume":"94","author":"Becker","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"yrv180004r24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/npp.2014.330","article-title":"Evaluation of opioid modulation in major depressive disorder.","volume":"40","author":"Ehrich","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"yrv180004r25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/AJP.0000000000000283","article-title":"Prevalence and correlates of suicidal thoughts and suicide attempts in people prescribed pharmaceutical opioids for chronic pain.","volume":"32","author":"Campbell","year":"2016","journal-title":"Clin J Pain"},{"key":"yrv180004r26","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1111\/j.1526-4637.2011.01131.x","article-title":"Depression, chronic pain, and suicide by overdose: on the edge.","volume":"12","author":"Cheatle","year":"2011","journal-title":"Pain Med"},{"issue":"7","key":"yrv180004r27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/add.13774","article-title":"Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration.","volume":"112","author":"Bohnert","year":"2017","journal-title":"Addiction"},{"issue":"6","key":"yrv180004r28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jemermed.2015.06.035","article-title":"Emergency visits for prescription opioid poisonings.","volume":"49","author":"Tadros","year":"2015","journal-title":"J Emerg Med"},{"issue":"6","key":"yrv180004r32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/17425247.2018.1473374","article-title":"What\u2019s holding back abuse-deterrent opioid formulations? considering 12 U.S. stakeholders.","volume":"15","author":"Pergolizzi","year":"2018","journal-title":"Expert Opin Drug Deliv"},{"issue":"19","key":"yrv180004r33","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1001\/jama.2018.4996","article-title":"Abuse-deterrent opioids.","volume":"319","year":"2018","journal-title":"JAMA"},{"key":"yrv180004r34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.drugpo.2017.12.003","article-title":"Multiple injections per injection episode: high-risk injection practice among people who injected pills during the 2015 HIV outbreak in Indiana.","volume":"52","author":"Broz","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"4","key":"yrv180004r36","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2105\/AJPH.2012.301209","article-title":"Longitudinal effects of universal preventive intervention on prescription drug misuse: three RCTs with late adolescents and young adults.","volume":"103","author":"Spoth","year":"2013","journal-title":"Am J Public Health"},{"key":"yrv180004r37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ypmed.2014.01.029","article-title":"Can we build an efficient response to the prescription drug abuse epidemic? assessing the cost effectiveness of universal prevention in the PROSPER trial.","volume":"62","author":"Crowley","year":"2014","journal-title":"Prev Med"},{"issue":"3-4","key":"yrv180004r38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ypmed.2012.12.013","article-title":"PROSPER community-university partnership delivery system effects on substance misuse through 6 1\/2 years past baseline from a cluster randomized controlled intervention trial.","volume":"56","author":"Spoth","year":"2013","journal-title":"Prev Med"},{"key":"yrv180004r40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0005-7894(03)80032-1","article-title":"Effectiveness of the Coping Power program and of classroom intervention with aggressive children: outcomes at a 1-year follow-up.","volume":"34","author":"Lochman","year":"2003","journal-title":"Behav Ther"},{"issue":"2","key":"yrv180004r41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2105\/AJPH.2017.304187","article-title":"Opioid crisis: no easy fix to its social and economic determinants.","volume":"108","author":"Dasgupta","year":"2018","journal-title":"Am J Public Health"},{"key":"yrv180004r42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/0024-3205(83)90529-5","article-title":"Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans.","volume":"33","author":"Kreek","year":"1983","journal-title":"Life Sci"},{"issue":"3","key":"yrv180004r43","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"yrv180004r44","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/bph.2015.172.issue-2","article-title":"BU08073 a buprenorphine analogue with partial agonist activity at \u00b5-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.","volume":"172","author":"Khroyan","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"2","key":"yrv180004r45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1151\/spp","article-title":"Practical considerations for the clinical use of buprenorphine.","volume":"2","author":"Jones","year":"2004","journal-title":"Sci Pract Perspect"},{"issue":"9358","key":"yrv180004r46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"10118","key":"yrv180004r47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"yrv180004r48","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial.","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"yrv180004r50","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"yrv180004r53","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"yrv180004r55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1056\/NEJMp1803982","article-title":"Methadone in primary care: one small step for congress, one giant leap for addiction treatment.","volume":"379","author":"Samet","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"yrv180004r56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1802741","article-title":"Primary care and the opioid-overdose crisis: buprenorphine myths and realities.","volume":"379","author":"Wakeman","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"yrv180004r57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1056\/NEJMp1804059","article-title":"Moving addiction care to the mainstream: improving the quality of buprenorphine treatment.","volume":"379","author":"Saloner","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"yrv180004r59","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMsa064115","article-title":"Release from prison: a high risk of death for former inmates.","volume":"356","author":"Binswanger","year":"2007","journal-title":"N Engl J Med"},{"issue":"2-3","key":"yrv180004r60","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.drugalcdep.2007.05.022","article-title":"A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release.","volume":"91","author":"Kinlock","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"yrv180004r61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry.","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"yrv180004r62","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jsat.2013.02.005","article-title":"Initiation of buprenorphine during incarceration and retention in treatment upon release.","volume":"45","author":"Zaller","year":"2013","journal-title":"J Subst Abuse Treat"},{"key":"yrv180004r63","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.","volume":"346","author":"Walley","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"yrv180004r64","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.","volume":"174","author":"Bachhuber","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"7","key":"yrv180004r66","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1377\/hlthaff.2015.1661","article-title":"Medical marijuana laws reduce prescription medication use in Medicare Part D.","volume":"35","author":"Bradford","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"yrv180004r67","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1176\/appi.ajp.2017.17040413","article-title":"Cannabis use and risk of prescription opioid use disorder in the United States.","volume":"175","author":"Olfson","year":"2018","journal-title":"Am J Psychiatry"},{"key":"yrv180004r1","volume-title":"2016 National Survey on Drug Use and Health: Detailed Tables","author":"Center for Behavioral Health Statistics and Quality","year":"2017"},{"key":"yrv180004r51","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-6974-2","volume-title":"Handbook of Methadone Prescribing and Buprenorphine Therapy","author":"Cruciani","year":"2013"},{"key":"yrv180004r52","volume-title":"Treatment Episode Data Set (TEDS): 2005-2015. National Admissions to Substance Abuse Treatment Services.","author":"Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality","year":"2017"},{"key":"yrv180004r58","volume-title":"Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007-2009: Special Report","author":"Bronson","year":"2017"},{"key":"yrv180004r65","author":"Powell","year":"2015"},{"key":"yrv180004r3","unstructured":"Centers for Disease Control and Prevention. Opioid Epidemic: Understanding the Epidemic. https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html. Accessed September 14, 2018."},{"key":"yrv180004r16","unstructured":"National Institute on Drug Abuse. Opioid summaries by state. https:\/\/www.drugabuse.gov\/drugs-abuse\/opioids\/opioid-summaries-by-state. Accessed July 9, 2018."},{"key":"yrv180004r29","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance Report, 2015. Vol 27. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-report-2015-vol-27.pdf. Accessed July 9, 2018."},{"key":"yrv180004r30","unstructured":"Centers for Disease Control and Prevention. Surveillance for viral hepatitis\u2013United States, 2015. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2015surveillance\/commentary.htm. Accessed July 9, 2018."},{"key":"yrv180004r31","unstructured":"US Department of Health and Human Services. Agency priority goal action plan: Reducing opioid morbidity and mortality. https:\/\/www.performance.gov\/health_and_human_services\/FY2018_Q1_HHS_Reducing_Opioid_Morbidity_and_Mortality.pdf. Accessed July 9, 2018."},{"key":"yrv180004r35","unstructured":"US Food and Drug Administration. Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm163647.htm. Accessed August 15, 2018."},{"key":"yrv180004r39","unstructured":"US Department of Health and Human Services. Facing Addiction in America: The Surgeon General\u2019s Report on Alcohol, Drugs, and Health. Washington, DC: US Dept of Health; 2016. https:\/\/addiction.surgeongeneral.gov\/. Accessed September 24, 2018."},{"key":"yrv180004r49","unstructured":"National Institute on Drug Abuse. How effective are medications to treat opioid use disorder? https:\/\/www.drugabuse.gov\/publications\/research-reports\/medications-to-treat-opioid-addiction\/efficacy-medications-opioid-use-disorder. Accessed July 9, 2018."},{"key":"yrv180004r54","unstructured":"Substance Abuse and Mental Health Services Administration. 2011 Opioid Treatment Program (OTP) Survey: Data on Substance Abuse Treatment Facilities with OTPs. BHSIS Series S-65, HHS Publication No. (SMA) 14-4807. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/OTP2011_Web\/OTP2011_Web\/OTP2011_Web.pdf"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2716982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T11:01:11Z","timestamp":1549450871000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.3126"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3126","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}